@article{83ee3b51d0d445e8a3ca1f89859e8adb,
title = "Production of dasatinib encapsulated spray-dried poly (lactic-co-glycolic acid) particles",
abstract = "Fibrotic scarring of the retina, termed proliferative vitreoretinopathy (PVR), can cause permanent visual impairment and blindness following corrective surgery for retinal detachment and/or ocular trauma. We have previously shown that multiple intravitreal injections of dasatinib prevent PVR in an animal model. The aim of this research was to develop injectable sustained release systems for dasatinib, which would be preferred for clinical use over multiple ocular injections. To accomplish this, dasatinib was encapsulated in Poly (lactic-co-glycolic acid) [PLGA] particles via a benchtop spray-drying process. Spray drying parameters were optimized using a taguchi statistical approach to obtain particle size between 0.5 and 1.5 μm. Characterization of two different sets of particles, sub-micron and >1.0 μm in average diameter, respectively, showed that dasatinib release from sub-micron particles lasts 15 days while release from particles with diameters >1.0 μm lasts up to 55 days. Zeta potential measurement of aqueous buffer suspended particles suggests sub-micron particles to be more stable in aqueous environment compared to >1.0 μm particles. Dasatinib released from these particles maintained therapeutic efficacy, as dasatinib incorporated PLGA particles significantly inhibited the contraction of collagen matrices compared to PLGA (control) particles when tested on an in vitro scar contraction assay.",
keywords = "Contraction assay, Dasatinib, Emulsion, PLGA, Poly (lactic-co-glycolic acid), Proliferative vitreoretinopathy, Spray dry",
author = "Rajat Chauhan and Rayeanne Balgemann and Christopher Greb and Nunn, {Betty M.} and Shunichiro Ueda and Hidetaka Noma and Kevin McDonald and Kaplan, {Henry J.} and Shigeo Tamiya and O'Toole, {Martin G.}",
note = "Funding Information: This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Broad Agency Announcement under Award No. W81XWH-15-1-0298 , as well as in part by an unrestricted grant from Research Prevent Blindness Inc., New York, NY , and University of Louisville grant (Kentucky, USA). Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The authors would like to thank Conn Centre for Renewable Energy Research (University of Louisville) for their support with SEM. Funding Information: This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Broad Agency Announcement under Award No. W81XWH-15-1-0298, as well as in part by an unrestricted grant from Research Prevent Blindness Inc. New York, NY, and University of Louisville grant (Kentucky, USA). Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The authors would like to thank Conn Centre for Renewable Energy Research (University of Louisville) for their support with SEM. Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",
year = "2019",
month = oct,
doi = "10.1016/j.jddst.2019.101204",
language = "English",
volume = "53",
journal = "Journal of Drug Delivery Science and Technology",
issn = "1773-2247",
}